Midatech Pharma (MTPH) Trading Down 14%

Midatech Pharma PLC (LON:MTPH)’s share price fell 14% during mid-day trading on Wednesday . The company traded as low as GBX 6.75 ($0.09) and last traded at GBX 6.75 ($0.09). 217,460 shares were traded during mid-day trading, an increase of 252% from the average session volume of 61,863 shares. The stock had previously closed at GBX 7.85 ($0.10).

The company has a debt-to-equity ratio of 28.58, a current ratio of 3.24 and a quick ratio of 1.10. The firm has a market capitalization of $37.92 million and a PE ratio of -0.27.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Stock Observer and is owned by of Stock Observer. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://www.thestockobserver.com/2019/04/26/midatech-pharma-mtph-trading-down-14.html.

Midatech Pharma Company Profile (LON:MTPH)

Midatech Pharma PLC, a specialty pharmaceutical company, focuses on developing and commercializing products in oncology and immunotherapy in the United States and the United Kingdom. The company operates through two segments, Pipeline Research and Development; and Commercial. Its products include Zuplenz, an oral soluble film for moderately emetogenic chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting; Gelclair, an oral gel barrier device indicated for the management and relief of pain due to oral mucositis; Oravig, an orally dissolving buccal tablet for oral thrush; and Soltamox, an oral liquid solution of tamoxifen citrate, for the treatment and prevention of breast cancer.

Read More: Why does a company issue an IPO?

Receive News & Ratings for Midatech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.